ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 258 filers reported holding ACCELERON PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $36,994,000 | +5689.4% | 214,959 | +4121.5% | 0.13% | +4333.3% |
| Q2 2021 | $639,000 | +161.9% | 5,092 | +182.9% | 0.00% | +50.0% |
| Q1 2021 | $244,000 | -39.5% | 1,800 | -42.9% | 0.00% | 0.0% |
| Q4 2020 | $403,000 | -88.9% | 3,155 | -90.2% | 0.00% | -90.0% |
| Q3 2020 | $3,624,000 | +377.5% | 32,200 | +304.3% | 0.02% | +300.0% |
| Q2 2020 | $759,000 | +94.6% | 7,965 | +83.8% | 0.01% | +150.0% |
| Q1 2020 | $390,000 | +27.0% | 4,334 | -25.3% | 0.00% | 0.0% |
| Q4 2019 | $307,000 | +29.0% | 5,800 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $238,000 | -67.4% | 5,800 | -63.1% | 0.00% | -60.0% |
| Q1 2019 | $731,000 | +28.9% | 15,713 | +20.7% | 0.01% | +25.0% |
| Q4 2018 | $567,000 | -58.4% | 13,016 | -45.3% | 0.00% | -50.0% |
| Q3 2018 | $1,362,000 | +274.2% | 23,800 | +155.9% | 0.01% | +300.0% |
| Q1 2018 | $364,000 | -79.9% | 9,300 | -78.3% | 0.00% | -77.8% |
| Q4 2017 | $1,815,000 | – | 42,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |